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Abstract
Key circulating molecules that link vitamin D (VD) to pediatric obesity and its co-morbidities remain unclear. Using a
proteomic approach, our objective was to identify key molecules in obese children dichotomized according to 25OH-
vitamin D (25OHD) levels. A total of 42 obese children (M/F = 18/24) were divided according to their 25OHD3 levels into
25OHD3 deficient (VDD; n = 18; 25OHD,15 ng/ml) or normal subjects (NVD; n = 24;.30 ng/ml). Plasma proteomic analyses
by two dimensional (2D)-electrophoresis were performed at baseline in all subjects. VDD subjects underwent a 12mo
treatment with 3000 IU vitamin D3 once a week to confirm the proteomic analyses. The proteomic analyses identified 53
‘‘spots’’ that differed between VDD and NVD (p,0.05), amongst which adiponectin was identified. Adiponectin was selected
for confirmational studies due to its tight association with obesity and diabetes mellitus. Western Immunoblot (WIB)
analyses of 2D-gels demonstrated a downregulation of adiponectin in VDD subjects, which was confirmed in the plasma
from VDD with respect to NVD subjects (p,0.035) and increased following 12mo vitamin D3 supplementation in VDD
subjects (p,0.02). High molecular weight (HMW) adiponectin, a surrogate indicator of insulin sensitivity, was significantly
lower in VDD subjects (p,0.02) and improved with vitamin D3 supplementation (p,0.042). A direct effect in vitro of 1a,25-
(OH)2D3 on adipocyte adiponectin synthesis was demonstrated, with adiponectin and its multimeric forms upregulated,
even at low pharmacological doses (1029 M) of 1a,25-(OH)2D3. This upregulation was paralleled by the adiponectin
interactive protein, DsbA-L, suggesting that the VD regulation of adiponectin involves post-transciptional events. Using a
proteomic approach, multimeric adiponectin has been identified as a key plasma protein that links VDD to pediatric obesity.
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Introduction
As with obesity, vitamin D (VD) deficiency is reaching epidemic
proportions worldwide, in both pediatric as well as adult
populations [1]. Evidence is accumulating to suggest that there
is a potential link between obesity and VD deficiency among
global populations [2,3]. Beyond vitamin D’s historic role in bone
mineralization to its more recent association with allergy
development [1,4], reports to date have linked VD deficiency to
hypertension, diabetes mellitus and insulin resistance (IR), non-
alcoholic fatty liver disease (NAFLD) and the metabolic syndrome
[1,3,5–11]. Consequently, VD deficiency may no longer be a
condition but rather a mediator of metabolic diseases responsible
for the long-term health outcomes of obese children.
Vitamin D is a group of fat soluble prohormones, with the two
major forms being ergocalciferol (VD2) and cholecalciferol
(VD3)[2,3]. In vivo, VD3 and VD2 are metabolized by the liver
to produce 25-dihydroxyvitamin D3 (25-OHD3) or 25-OHD2.
These metabolites are then further metabolized by the kidney to
produce the bioactive forms 1a,25-(OH)2D3 and 1a,25-(OH)2D2.
The bioactive form of VD3, 1a25-dihydroxyvitamin D3 (1a,25-
(OH)2D3), functions as a pleiotropic hormone controlling gene
expression in numerous cell types and tissues regulating prolifer-
ation, differentiation and cell survival [1]. These activities are
achieved principally via the cytosolic/nuclear vitamin D receptor
(VDR) signal-transduction pathways and VD responsive elements
(VDRE) found on numerous key genes, with rapid responses
occurring via VDR localized in the plasma and endoplasmic
reticulum (ER) membranes [12]. The VDR has been found in
more than 40 tissues including pancreatic beta-cells, smooth
muscle cells, monocytes and adipocytes [13]. As such, it is
hypothesized that VD deficiency could lead to complex disease
phenotypes, including obesity.
Excess body fat is associated with an increased risk of
suboptimal VD status [3,14]. It is, however, unclear as to whether
poor VD status is a consequence of obesity or is actively involved
in its development [1–3]. Until now, data regarding the role of VD
are inconclusive as the majority of results are derived from
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association studies, with intervention and longitudinal studies
lacking [15]. Cross-sectional studies have principally focused on
classical cardiovascular risk factors such as blood pressure, fasting
glucose and lipids in both adults and children [11,16], with studies
in pediatric subjects revealing that different VD cut-offs relate to
specific cardiovascular outcomes [11,17]. While respecting that a
role exists, the links between VD and obesity remain to be
elucidated.
In the search for biomarkers that are representative of
individual disease states, proteomic analyses can evaluate globally
expressed and activated protein pathways in both physiological
and pathological conditions. A proteomic approach can differen-
tiate phenotypes of diseases as well as investigate mechanisms for
target therapies. Recently, a proteomic study conducted in adult
obesity revealed that VD binding globulin could be a marker of
changes in body fat mass [18]. As such, to investigate a functional
relationship between VD status and pediatric obesity, the aim of
this study was to firstly using a proteomic approach, target
potential plasmatic biomarkers that could link VD deficiency to
pediatric obesity. The second aim was to then verify that such
markers could be modulated by VD supplementation in vivo, and
finally to confirm such effects in vitro and shed light as to the
biological mechanisms involved in the direct effect of 1a,25-
(OH)2D3.
Subjects and Methods
Subjects
In this study, we recruited consecutively 97 children and
adolescents aged between 5–18 yrs referred to the Pediatric
Endocrine Service of the ‘‘Ospedale Maggiore della Carita`’’ in
relation to obesity from October 2009. Subjects were eligible if
they were healthy, had a body mass index (BMI) that exceeded the
95th percentile according to the Italian growth charts [19], were
diet-naı¨ve and presented 25-OHD3 levels ,15.0 ng/ml (deficien-
cy; VDD) or.30 ng/ml (sufficiency; NVD). The level of 15.0 ng/
ml 25-OHD3 was chosen as it represents the value below which
cardiovascular risk factors are significantly associated to 25-OHD3
in children and adolescents, as described by the National Health
and Nutrition Examination Survey [10], as well as in adults [16].
Subjects with intermediate 25-OHD3 levels (15.0–30.0 ng/ml)
were excluded from the study to avoid the potential interference of
VD hypovitaminosis. Exclusion criteria included the presence of
diabetes mellitus, the use of pharmaceuticals which could influence
glucose and lipid metabolism, blood pressure or appetite, as well as
endocrine or genetic obesity, or a low birth weight.
The protocol was conducted in accordance with the declaration
of Helsinki of 1975 as revised in 1983 and was approved by a
Local Ethic Committee (Ethics Committee AOU ‘‘Maggiore della
Carita`’’ di Novara, ASL BI, ASL NO, ASL VC ASL VCO;
protocol 199/CE; study CE 14/11; www.maggioreosp.novara.it).
A written informed consent was obtained by all parents before the
evaluations where the purpose of the study was carefully
explained.
Anthropometric and biochemical measurements
All the subjects underwent a clinical evaluation using the Italian
growth charts [19]. Subjects which were assigned to VDD (n = 18),
were evaluated at baseline and after 6–12mo. Each received 3000
IU cholecalciferol (VD3) once a week (corresponding at about 400
IU daily) according to the recommendations American Academy
of Pediatrics 2008 [20].
Pubertal stages were determined by an assigned group of
trained physicians, using the criteria of Marshall and Tanner [21].
Height was measured to the nearest 0.1 cm by the Harpenden
stadiometer and weight with light clothing to the 0.1 kg by using a
manual scale. BMI was calculated as body weight divided by
squared height (kg/m2). BMI standard deviation score (BMISDS)
was calculated with the LMS method [19]. Waist circumference
(WC) was measured at the high point of the iliac crest around the
abdomen and was recorded to 0.1 cm. Systolic (SBP) and diastolic
(DBP) blood pressure were measured three times on the left arm
after 15 min at rest in the supine position and prior to other
physical evaluations, by using a standard mercury sphygmoma-
nometer; the average was used for analyses.
After a 12 h overnight fast, morning blood samples for
proteomic analyses, glucose, insulin and 25-OHD3 were obtained.
All subjects underwent an OGTT (1.75 g of glucose solution per
kg, maximum 75 g). Insulin resistance and sensitivity were
calculated using the formula of HOMA-IR and Matsuda index,
respectively. Glucose was expressed in mg/dl (1 mg/
dl:0,05551 mMol/liter) and insulin in mUI/ml (1 mUI/
ml = 7.175 pmol/l). All measurements were performed using
standardized methods in the hospital’s analysis laboratory.
Vitamin D as 25OHD3 serum levels (ng/ml) were assayed by a
direct competitive chemiluminescent immunoassay with a CV
value of 4% (LiaisonH Test 25OHD total, DiaSorin Inc, Stillwater
MN-USA). Human total adiponectin (mg/ml) was measured by the
method of ELISA according to the manufacturer’s instructions
(AdipoGen Inc, Incheon, Korea), with the intra-assay and inter-
assay coefficients of variation 3.8% and 5.5%, respectively. The
sensitivity of the assay was 0.0001 mg/ml. Human unacylated
ghrelin (pg/ml) was also measured by ELISA (BioVendor, Brno,
Czech Republic), with the intra-assay and inter-assay coefficients
of variation 4.4% and 4.5%, respectively. The sensitivity of the
assay was ,5 pg/ml. Formulas and other assays were previously
described [22].
2D-Electrophoresis
To prepare platelet-free plasma for 2D-electrophoresis, all
samples were centrifuged at 1300 rpm, 4C for 10 min followed by
a further centrifugation at 2400rcf 4uC for 15 min, with storage at
–80uC. Plasma protein concentrations were determined by using
the DC Protein Assay (BioRad, Hercules, CA). To reduce
biological variation in the proteomic analysis, as described by
Mischak et al., 2010 [23], a minimum of 12 samples per group was
delineated. For the 1st dimension, equal volumes of plasma within
the range of 50 ug of protein per analysis, were re-suspended in
rehydration buffer, according to the method of de Roos et al.,
2008 [24] and loaded onto a 7 cm immobilized pH gradient (IPG)
3–10 strip for an overnight (O/N) active in-gel rehydration
(BioRad). Isoelectric focusing (IEF) was performed at 20uC with a
Protean IEF Cell (BioRad) using a total of 10,000 V/h with a
maximum of 8,000 V. For the 2nd-dimensional separation, the
IPG strips were soaked, firstly in a reduction equilibration buffer
(6 M Urea, 2%SDS, 0.375 M Tris-HCl pH8.8, 20% glycerol 2%
w/v DTT), followed by an alkylation buffer (6 M Urea, 2%SDS,
0.375 M Tris-HCl pH8.8, 20% glycerol 2.5% w/v iodoacetamide;
BioRad). The strips were then positioned in 10% SDS-polyacryl-
amide gels (SDS-PAGE) run at 200 V for 40 min. Polyacrylamide
gels were fixed in 10% methanol, 7% acetic acid and resolved
protein spots visualized with an O/N incubation in Sypro-Ruby
fluorescent total protein stain (BioRad). All samples were evaluated
in duplicate.
Image analysis
Fluorescent images of individual gels were captured with a
ChemiDoc Imager using a 615–645 nM filter (630BP30; BioRad)
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and analyzed using PDQuest software (version 8.0) according to
the manufacturer’s recommendations. Briefly, the software per-
forms an automated detection and matching of spots from all gels,
calculating individual spot ‘‘volumes’’ by density/area integration
with Sypro-Ruby filtration and Gaussian modeling. To control for
slight differences in protein loading across gels, the individual spot
volumes were also normalized to the total spot volume for each
gel. For each protein spot, an average value for VDD and NVD
were compared and subjected to Student’s t-test to determine the
spots that were significantly different between the two groups.
Only those spots that showed a statistically significant difference
with a p,0.05, were chosen for PDQuest isoelectric point (pI) and
molecular weight (MW) estimations and identification.
Western immunoblot (WIB)
Independent of the experiments performed, all samples were
size-fractionated on 10% SDS-PAGE under reducing or non-
reducing (NR) conditions and electro-transferred to immuno-blot
polyvinylidene difluoride (PVDF) membrane (BioRad). For both
plasma and conditioned medium (CM) under NR and R
conditions, membranes were incubated with monoclonal anti-
adiponectin (Adipogen, Inc Incheon Korea) and detected with the
appropriate horseradish peroxidase-conjugated secondary anti-
body (Chemicon Millipore, Temecula, CA). Likewise, whole cell
lysates (WCL) were analyzed with anti-DsbA-L (Abcam, Cam-
bridge, UK) and anti-a Tubulin (Sigma). Total protein from CM
was assessed by Ponceau S staining and used for normalization
(Sigma). Immunoreactive proteins were detected using enhanced
chemiluminescence (Pierce Biotechnology, Rockford, IL) with
image capture performed using CCD-camera linked to ChemiDoc
(BioRad). Results, were quantified using QuantityOne software
with values presented as arbitrary units (AU) normalized to total
protein concentrations.
3T3-L1 cell culture and treatments
To address the direct effect of 1a,25-(OH)2D3 on adipose tissue
(AT), the well characterized murine 3T3-L1 preadipocyte cell
model was utilized (European Collection of Cell Cultures). The
preadipocytes were grown to confluency in their maintenance
medium (Dulbecco’s modified Eagle’s medium supplemented with
10% FBS and 1% penicillin/streptomycin; Sigma) at which the
cells were induced to differentiate with the addition of 500 uM
isobutylemthylxanthine (IBMX; Sigma), 25 uM dexamethasone
(DEX; Sigma) and 0.5 ug/ml insulin (Sigma) for 3 d, following
which the medium was changed to straight insulin containing
medium for an additional 3 d. To complete differentiation, the
medium was returned to maintenance medium for a further 4 d,
giving a total of 10 d for the formation of adipocytes. At this time,
the adipocytes were then placed into serum-free medium (SFM)
with an equal volume of vehicle (ethanol), or SFM with 1029 M or
1027 M 1a,25-(OH)2D3 (Sigma) and left to incubate for up to
48 h, with aliquots of conditioned medium (CM) removed at 7, 24
and 48 h. Aliquots were centrifuged at 1000 rpm at 4C and stored
at 220C prior to electrophoretic analyses. At the 48 h time point,
WCL were prepared using RIPA buffer (20 mM HEPES pH 7.4,
150 mM NaCl, 1% Triton-X 100, 1% sodium deoxycholate, 0.1%
SDS, SIGMAFAST EDTA free protease inhibitor cocktail; Sigma)
with concentrations determined using the BCA Protein Assay
(Pierce, Rockford, IL).
Statistical analysis
Data are expressed as mean 6 SEM. Skewed variables were
logarithmically transformed before analyses when necessary.
Differences between groups, treatments and in vitro studies were
compared using Mann-Whitney U or Wilcoxon test, Student’s t-
test or ANCOVA with BMISDS, age and sex as covariates, where
appropriate. Statistical significance was assumed for p,0.05. The
statistical analyses were performed with SPSS for Windows version
17.0 (SPSS; Chicago, IL).
Results
Baseline evaluations
Of the 97 original subjects, 55 were excluded because they did
not satisfy the inclusion criteria to do the proteomic analyses with
respect to their 25-OHD3 levels (VDD: ,15 ng/ml; NVD
.30 ng/ml). The final dataset included 42 participants, aged
between 5–18 yrs (18 M/24 F). Of these, 18 were classified VDD
(range: 5.40–14.20 ng/ml), with the remainder falling into the
group NVD (range: 31.20–50.0 ng/ml) without differences in
seasonal distribution of the samples. Age and Tanner stages were
similar between the two groups. Basal evaluations demonstrated
that VDD subjects were more obese, more insulin-resistant and
had higher fasting glucose and DBP, when compared to NVD.
The clinical and biochemical characteristics of VDD and NVD
are shown in Table 1.
2D-electrophoretic analysis
Plasma from both VDD and NVD subjects were analyzed by
2D-electrophoresis blinded to evaluate differences in the expres-
sion and post-translational modifications (PTM) of circulating
proteins. A global analysis using IPG 3-10 in duplicate for each
subject, identified, when corrected for Sypro-Ruby background
anomalies, 53 ‘‘spots’’ that were significantly different between the
two groups (p,0.05), with the top ten most significant spots
identified by PDQuest shown (Table 2). Of the 53 spots, 51% were
downregulated. Amongst the spots predicted to be downregulated
between VDD and NVD, was the adipokine adiponectin (ID
3050) identified using Swiss-Prot human plasma database analysis
in combination with Tagldent Searches (http://web.expasy.org)
Table 1. Basal clinical and biochemical characteristics of
subjects.
NVD (25OHD .
30 ng/mL) VDD (25OHD ,15 ng/mL)
M/F 8/16 10/8
PP/P 12/12 8/10
25OHD (ng/dl) 37.061.1 11.060.5****
BMI (Kg/m2) 25.660.7 28.361.3*
BMISDS 1.80460.100 2.09460.130***
W/H 0.5960.01 0.6260.10
SBP (mmHg) 121.463.3 122.563.1
DBP (mmHg) 79.762.1 85.262.6***
Glc0’ (mg/dl) 85.261.8 89.161.5**
Ins0’(mUI/l) 13.961.2 14.662.1
HOMA 2.960.2 3.260.5**
Matsuda index 4.4460.67 3.4760.28**
Adiponectin (AU) 8594.66578.2 7189.16383.6***
AU: arbitrary unit; BMI: body mass index; DBP: diastolic blood pressure; F:
female; Glc0’: fasting glucose; HOMA: homeostatic model assessment; Ins0’:
fasting insulin; M: male; PP: prepubertal: P: pubertal; SBP: systolic blood
pressure: * p = 0.06; ** p,0.05; *** p,0.03; **** p,0.0001.
doi:10.1371/journal.pone.0083685.t001
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with pI and MW PDQuest estimates (Figure 1). A WIB analysis of
2D-electrophoretic gels using an adiponectin specific antibody,
identified 2 adiponectin monomeric isoforms within the pI5.4/
30kDa range, providing further evidence that the original ‘‘spot’’
could be adiponectin and a PTM of adiponectin (Figure 1).
Adiponectin confirmational evaluation
Adiponectin was selected for confirmational studies due to its
strong correlation with obesity and its co-morbidities, as well as its
localization within one of the susceptibility gene loci for obesity
[25]. Two approaches were utilized to confirm the differences in
plasma adiponectin expression between VDD and NVD obese
pediatric subjects. In the first, WIB analyses of 2D-electrophoretic
gels were performed in 10 subjects from each group, with this
approach demonstrating qualitatively reduced total adiponectin in
subjects with ,15 ng/ml 25-OHD3 (VDD; Figure 2A). In the
second approach, densitometric WIB evaluations (VDD vs NVD;
71876383 vs 85946587 AU; p,0.035; Figure 2B) and ELISA
evaluations (VDD vs NVD; 6.060.8 vs 10.961.9 mg/ml; p,0.05)
of circulating total adiponectin in all subjects, further confirmed
that total adiponectin is reduced in pediatric obese subjects with
,15 ng/ml 25-OHD3 with no alteration in the significance when
corrected for BMI-SDS, age and sex.
Adiponectin circulates in plasma in three major forms: trimers/
low molecular weight (LMW), hexamers/medium-MW (MMW)
and high-MW (HMW), with the HMW form shown to be the most
bioactive, particularly with respects to insulin action [25]. To
dissect changes in the adiponectin isoforms, an evaluation using
non-reduced (NR)-WIB of plasma from both VDD and NVD
subjects was performed. While showing that HMW, MMW and
LMW forms were all significantly lower in VDD subjects, the
greatest difference was observed for HMW adiponectin (VDD vs
NVD; 697.16127.7 vs 1270.56198 AU; p,0.013; Figure 3).
VD-treatment: Clinical and adiponectin evaluations
To understand the benefits of VD3 therapy, the original 18
VDD were administered 3000 IU cholecalciferol (VD3) once a
week, for a 12mo study. Of the 18 subjects, 10 concluded the
study, while the remainders discontinued the treatment with
cholecalciferol or dropped out with clinical controls. In the 10
VDD subjects, 25-OHD3 levels increased during the course of the
treatment (10.660.6 vs 20.464.8 ng/ml; p,0.04), while DBP
(84.264.6 vs 77.563.2 mmHg) and fasting glucose (88.063.1 vs
Figure 1. Proteomic evaluation predicts adiponectin isoforms as being differentially expressed between VDD and NVD. A 2D-
electrophoretic analysis was performed in duplicate for the 42 subjects using IPG3-10, with proteins detected by Sypro Ruby staining. Spot/s
predicted to be adiponectin are indicated by the PDQuest identification number (SSP3050). Supportive evidence for the prediction was given by
performing a WIB of 2D-electrohoretic gels using anti-adiponectin antibody. Representative gels are shown.
doi:10.1371/journal.pone.0083685.g001
Table 2. Top ten most significantly modulated plasma proteins between VDD and NVD obese pediatric subjects.
PDQuest ID
VDD Media n=18
(AU)
NVD Media n=24
(AU) P-value VVD vs NVD MW kDa* pI* Protein ID** Accession No.
302 35.1 75.5 0.007 54 4.8 N/D*** -
601 28.9 12.7 0.008 100 3.2 N/D -
1101 30.2 20.9 0.01 39 4.8 N/D -
1103 278 348.8 0.04 40 5.2 Haptoglobin b P00738
1402 128.2 94.5 0.04 62 4.8 N/D -
2301 278.2 216.2 0.04 55 5.0 N/D*** -
3003 84.1 63.5 0.006 26 5.5 N/D -
3050 22.8 31.3 0.03 28 5.4 Adiponectin Q15848
6603 18.6 60.3 0.02 100 6.4 N/D -
7305 53.7 42.8 0.02 55 6.3 N/D -
*PDQuest estimate; ** Confirmed by WIB; N/D =not determined; *** Under investigation.
doi:10.1371/journal.pone.0083685.t002
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81.563.1 mg/dl) decreased (p,0.05) without significant changes
in other parameters or BMI (26.161.7 vs 26.362.1 Kg/m2) at 12
months. When corrected for BMISDS, age and sex, the
significance for fasting glucose was lost. To overcome the absence
of a direct measurement of fat tissue, we measured visceral
adiposity index (VAI), an indicator of visceral adiposity status and
function [26], body adiposity index (BAI), which correlates more
than BMI with the percentage of body fat measured by dual
energy X-ray absorptiometry [27] and ghrelin which increases in
case of adiposity loss [28]. Waist circumference (90.263.9 vs
91.365.3 pg/ml), waist-to-height ratio (0.6360.02 vs 0.6360.05),
VAI (1.89360.337 vs 1.85260.343), BAI (0.05660.001 vs
0.05860.002 Kg/m2), and ghrelin (106.0621.1 vs
98.1630.6 pg/ml) did not change from baseline to T12 suggesting
that fat mass did not decrease over time.
With respects to adiponectin levels, a gradual and modest, yet
significant improvement in total adiponectin was observed over
the 12mo period, as demonstrated by WIB (Figure 4A). Similar
results were also observed for the multimeric forms of adiponectin
in circulation. The NR-WIB analysis demonstrated that both the
HMW and MMW forms improved modestly yet significantly with
cholecalciferol therapy, while alterations in LMW adiponectin did
not reach significance (Figure 4B). Correction for covariates did
not modify the results.
Vitamin D3 treatment upregulates adiponectin and
disulfide bond-A oxidoreductase-like protein (DsbA-L)
promoting adiponectin multimerization in 3T3-L1 mature
adipocytes
To examine the direct effect of VD on adipocytes, the cellular
component of AT exclusively responsible for the production and
secretion of adiponectin, 3T3-L1 cells were induced to differen-
tiate into adipocytes. Adipocytes were then treated for a further
48 hr period in SFM with or w/o increasing concentrations (1029
– 1027 M) of the bioactive form of VD3, 1a,25-(OH)2D3, with
aliquots of CM removed at 7, 24 and 48 hr. A WIB analysis of
monomeric adiponectin in the CM, demonstrated a significant
increase in total adiponectin secretion with increasing concentra-
tions of 1a,25-(OH)2D3 and with respect to time (n = 4; Figure 5).
An evaluation of the secretory capacity of the cells by examining
total protein within the CM, demonstrated that secretory profile is
unchanged and as such the upregulation of adiponectin secretion/
production by 1a,25-(OH)2D3 is selective. We also observed with
the higher concentration of 1a,25-(OH)2D3, while adiponectin
accumulation in the CM continued, there was a deterioration in
cell quality and a-tubulin expression, as such the lower concen-
tration was selected for further investigations (data not shown),
with the most significant changes evident for LMW form which
increased 8-fold (p,0.01) over the time period (Figure 6). An
analysis of the adiponectin interactive protein, DsbA-L, which has
been demonstrated to promote adiponectin multimerization in
adipocytes [29,30], demonstrated a higher expression level in 3T3-
L1 adipocyte cell lysates treated with 1029 M 1a,25-(OH)2D3 for
48 hr with respect to SFM, supporting the increased multi-
merization of adiponectin following 1a,25-(OH)2D3 treatments
Figure 2. WIB of proteomic analyses and plasma samples
confirms that total adiponectin is decreased in VD deficient
pediatric obese subjects (VDD) when compared to pediatric
obese with normal VD levels (NVD). A. A WIB of 2D-electrophoretic
analyses was performed in VDD (n= 10) and NVD (n= 10) subjects using
anti-adiponectin antibody. B. A WIB analysis under reduced conditions
of total adiponectin in the plasma of representative VDD (,15 ng/ml)
and NVD (.30 ng/ml) subjects.
doi:10.1371/journal.pone.0083685.g002
Figure 3. The multimeric forms of adiponectin are reduced, in particular the HMW form, in VD deficient pediatric obese subjects. A
WIB analysis under non-reduced conditions and a quantitative densitometric analysis of the multimeric forms of adiponectin (HMW, MMW, LMW) in
the plasma of representative VDD (,15 ng/ml; n = 18) and NVD (.30 ng/ml; n = 24) subjects. Densitometric results were normalized to plasma
protein concentrations.
doi:10.1371/journal.pone.0083685.g003
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(Figure 6). It is important to note that while there was an overall
increase in adiponectin multimerization in treated 3T3-L1 cells,
there was a clear predominance of the LMW form in both the
basal and treated state in clear contrast to the profile present in
human plasma samples.
Discussion
Pediatric obesity is an emerging health issue in many developed
countries, with repercussions later in life. Like adult obesity, it is
conceivable that genotype, lifestyle and behavioral factors such as
energy intake together with the levels of physical activity, play
critical roles in the obesity epidemic. There is, however, now
evidence suggesting that VD may contribute to the regulation of
weight gain, particularly in association to energy-restricted diets
[3]. As such, VD status has been proposed as a promising strategy
for the prevention of obesity and the development of its associated
complications. To date though, results of clinical studies regarding
the role of VD in obesity are inconclusive, with the ‘‘concert’’ of
metabolic signaling pathways that link obesity with VD status,
undefined [15]. In the present study, we used a proteomic
approach to identify potential in vivo biomarkers that could provide
a link between VD deficiency and pediatric obesity. Using this
technology, the multimeric forms of adiponectin, in particular the
HMW form, were identified as being downregulated in obese
pediatric subjects with vitamin D deficiency which in turn could be
upregulated with VD3 supplementation, independently of BMI.
Further, a direct effect of 1a,25-(OH)2D3 on adipocytes was
demonstrated, with adiponectin and its multimeric forms, as well
as the adiponectin interactive protein, DsbA-L, upregulated by
1a,25-(OH)2D3 treatment at low pharmacological concentrations.
The cohort of children enrolled in the present study who were
VD deficient, were more obese, more insulin-resistant and had
higher fasting glucose and DBP. These data are in agreement with
those found in a larger population covering the pediatric age
[10,31]. In particular, higher fasting glucose and blood pressure
levels observed in our cohort are in line with data of 2001–2004
National Health and Nutrition Examination Survey in US
adolescents [10]. VD deficiency is common in obese patients
and it is possible that this is the result of many factors, such as a
decreased VD bioavailability due to sequestration in adipose tissue
[32], low dietary VD intake due to poor nutritional habits and
minimal sun exposure due to a sedentary indoor lifestyle [33].
Although it is known that morbid obesity is directly correlated with
higher insulin resistance, fasting glucose levels and other comor-
bidities such as hypertension, VD deficiency is associated with
numerous biomarkers of systemic inflammation and metabolic
impairment, regardless of the total fat mass [10]. Moreover, the
15 ng/ml or less of VD may be the threshold by which VD
deficiency confers negative effects on insulin sensitivity [10,34] and
also hazard ratio for cardiovascular events [17]. We showed that 1
year cholecalciferol treatment improved DPB and fasting glucose
without significant changes in terms of BMI. Although in a small
group of children, these data are in line with other observations in
some pilot studies in animals [35] and in adults [36]. As our
patients did not improve their weight, our results seem dependent
on VD without an influence of body fat changes. It has to be
underlined that our children increased VD levels at the threshold
of deficiency for bone effects [15], suggesting that pleiotropic
actions other than those on bone would be exerted at different
levels as suggested by cross sectional studies which indicate 15 ng/
ml as the cut off for the cardiovascular disease risk [10,34].
Figure 4. Total and the HMW andMMWmultimeric forms of adiponectin increase in VD deficient pediatric obese subjects following
cholecalciferol supplementation for 12mo. A. A WIB analysis under reduced conditions and a quantitative densitometric analysis of total
adiponectin in the plasma of representative VDD (,15 ng/ml) and NVD (.30 ng/ml) subjects. B. A WIB analysis under non-reduced conditions and a
quantitative densitometric analysis of the multimeric forms of adiponectin in the plasma of VDD (,15 ng/ml; n = 18) and NVD (.30 ng/ml; n = 24)
subjects.
doi:10.1371/journal.pone.0083685.g004
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To explore the ‘‘concert’’ of metabolic signaling pathways
which underlie the link between VD deficiency and obesity, a 2D-
based proteomic methodology investigated the global changes in
expression levels as well as PTMs associated with VD status. In our
cohort of pediatric obese subjects divided according to their
circulating levels of 25-OHD3, adiponectin was identified and
confirmed to be significantly decreased in 25-OHD3 deficient
obese pediatric subjects. Adiponectin has been demonstrated to
have insulin-sensitizing effects [37], regulates centrally food intake
and body weight [38] and possesses cardioprotective [39], anti-
inflammatory and anti-oxidant properties [40], demonstrating that
it has a clear clinical relevance with respect to obesity and its
associated complications. Adiponectin is abundantly produced by
adipose tissue with its synthesis and secretion specific to adipocytes
[41] In contrast to other adipokines, circulating adiponectin is
negatively correlated with BMI and is decreased further in patients
with insulin resistance, type 2 diabetes and cardiovascular disease
[37]. In the present study, we observed within the pediatric obese
population a further subdivision in circulating total adiponectin
levels according to VD levels, with VD deficient subjects
presenting significantly lower levels of circulating adiponectin.
Within the circulation, adiponectin is present in three multi-
meric forms: trimer (LMW), hexamer (MMW) and HMW (12–18
monomers), with the HMW form considered to be the key
bioactive form, particularly with respect to insulin action
[25,37,42]. In the present study, we demonstrated that all
molecular weight forms were decreased in those with VD
deficiency with all analyses performed. Circulating concentrations
of adiponectin are known to be significantly decreased with the
development of obesity and with altered glycemic control with the
HMW form more strictly involved in insulin resistance [25,37,42].
From a clinical perspective it can be hypothesized that total
adiponectin and its multimeric forms were reduced in VD
deficient children because they are more obese. However, in the
present study we have shown an increase in circulating
adiponectin levels, in particular of HMW form, after 1 yr
cholecalciferol treatment. This significant improvement occurred
regardless of weight reduction, suggesting a direct role of VD. The
significantly higher levels of adiponectin could be one of the key
factors which contribute to the shown improvement of their
metabolic phenotype, as previously demonstrated by numerous
studies (for review see 36), including in children where an increase
in HMW adiponectin was shown to be correlated with an
improvement in insulin sensitivity [43,44].
With the in vivo data supporting a direct role for VD in the
regulation of adiponectin, and to confirm that VD yields an effect
on adiponectin expression, the direct effect of VD on adiponectin
secretion was tested using the murine 3T3-L1 adipocyte cell
model. It is known that nuclear and membrane VDR have been
demonstrated in a large array of tissues, including adipose tissue
[45] and is expressed in 3T3-L1 cells, with the highest expression
observed during the early stages of adipocyte differentiation where
Figure 5. Total adiponectin secretion increases in 3T3-L1 adipocytes treated with 1a,25-(OH)2D3. 3T3-L1 adipocytes, generated using a
standard differentiation protocol, at day 10 were treated with increasing concentrations of 1a,25-(OH)2D3 (1029 to 1027 M) in SFM or SFM with
vehicle for 48 h. The CM at 7, 24 and 48 h from the same treatment was analyzed by WIB under reduced condition and analyzed densitometrically for
the synthesis of adiponectin. Results were normalized to a-tubulin and are presented as fold-increase with respect to the 7 h SFM sample (n = 4).
doi:10.1371/journal.pone.0083685.g005
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VD has been shown to inhibit the differentiation process [46,47].
In the present investigation, we conferred with the clinical
observations in VD deficient pediatric obese subjects, with
adiponectin secretion and the multimeric forms increasing in
3T3-L1 mature adipocytes following 1a,25-(OH)2D3 supplemen-
tation, with significant effects observed at very low pharmacolog-
ical concentrations.
Previous studies regarding the direct effects of 1a,25-(OH)2D3
on adipose tissue are controversial with both inflammatory and
anti-inflammatory effects being reported [48–50]. Lorente-Ceb-
ria´n et al., [47] reported a downregulation in the secretion of total
adiponectin in human sub-cutaneous-AT (SAT) primary culture
differentiated adipocytes treated with 1a,25-(OH)2D3, with no
effect on mRNA expression. They also observed a downregulation
in the pro-inflammatory marker monocyte chemoattractant
protein-1 (MCP-1), supporting the concept of dual roles for
1a,25-(OH)2D3 in adipose tissue inflammation. A downregulation
of key pro-inflammatory markers by 1a,25-(OH)2D3 was also
demonstrated by Gao et al., [50] specifically in preadipocytes,
suggesting that the preadipocyte population is the major source of
proinflammatory mediators. A possible explanation for the
divergent results is that these studies observed their effects using
10-100-fold higher concentrations of 1a,25-(OH)2D3 than that
used in the present investigation, where we observed that such
concentrations had deleterious effects on adipocytes, most likely
through the activation of the Ca2+-mediated apoptotic pathway
[12]. Other differences between the study by Lorente-Cebria´n et
al., [49] and the present investigation, is the use of adult human
female primary culture SAT adipocytes versus murine 3T3-L1
adipocytes. Further, our study was not directed solely to total
adiponectin secretion, but it also examined the multimeric
adiponectin secretory profile following 1a,25-(OH)2D3. Here we
observed an altered distribution in the CM of these cells when
compared to a human plasma profile, with a clear predominance
of the LMW form, suggesting clear species diversity with respect to
the synthesis and secretion of adiponectin. Our experiments were
also performed in SF conditions suggesting in addition to species
diversity, they may also be a dependence on other serum activators
in the regulation of adiponectin which were absent in our study.
Overall, while our in vitro data support our clinical findings, it
would be of relevance to approach our in vivo findings using human
adipocytes addressing at the same time the depot specific
differences in adiponectin secretion as previously described [51],
excluding also the sex related differences as well as those likely
present between adults and children.
While in the present study it can’t be excluded that there is a
direct effect of 1a,25-(OH)2D3 on 3T3-L1 adipocyte transcrip-
tion, it is feasible that the increased synthesis and multimerization
of adiponectin is dependent on the induction of endoplasmic
reticulum (ER) genes involved in the post-translational process of
multimerization. In fact, we observed in response to low
concentrations of 1a,25-(OH)2D3, an increase in the ER-
chaperon DsbA-L protein, a key regulator of adiponectin folding
and assembly [52], which paralleled the increase in adiponectin
synthesis and multimerization. The expression levels of DsbA-L
are regulated in response to ER-stress and have been shown to be
significantly reduced in obese subjects and mice [29,30]. While we
observed that the ratio of LMW to the MMW and HMW were
diverse to the human plasmatic profiles, most likely a result of
species diversity or the absence of a key regulatory protein/s in the
SF CM, the results are in concordance with other studies using
thiazolidinediones [53]. Taken together, these results demonstrate
that increase in adiponectin levels and multimerization by 1a,25-
(OH)2D3, may occur via post-transcription-dependent mecha-
nisms involving ER proteins, such as DsbA-L.
There are limitations in the present study. The first is the
absence of true body fat measurements through radiological
techniques. It can be speculated that adiponectin changes are due
to changes in fat mass, however our subjects did not improve their
weight in terms of BMI, which is a good surrogate measurement
for body fat in obesity [54]. Moreover, BMISDS, waist, waist-to-
height-ratio, BAI, VAI and ghrelin levels did not change,
suggesting that fat mass did not decrease. Further, it has been
demonstrated that the impairment of total and HMW-adiponectin
levels in childhood obesity is different to adult obese patients,
showing less of a relationship with body fat content [44]. Similarly,
recent placebo controlled studies in humans observed an increase
in adiponectin during VD supplementation [55,56]. Furthermore,
BAI which has been demonstrated to be a good indirect marker of
body fat percentage and is superior to BMI [27], was unchanged,
supporting the hypothesis that adiponectin is modulated by VD.
Similarly, VAI, which has been proposed to be an indirect marker
of visceral adipose dysfunction [26], remained unchanged. It has
been demonstrated that with the increase of VAI, adiponectin
progressively decreases [57]. The fact that VAI remained
unchanged and adiponectin increased in our population treated
Figure 6. The secretion of the adiponectin multimeric forms, in
particular the LMW form, in parallel with the ER-chaperon
DsbA-L, increases in 3T3-L1 adipocytes treated with 1a,25-
(OH)2D3. 3T3-L1 adipocytes, generated using a standard differentia-
tion protocol, at day 10 were treated with increasing concentrations of
1a,25-(OH)2D3 (10-9 to 10-7M) in SFM or SFM with vehicle for 48 h. The
CM at 7, 24 and 48 h from the same treatment and CL at 48 h, was
analyzed by WIB under non-reduced or reduced conditions for the
synthesis of adiponectin multimeric forms or DsbA-L with a-tubulin,
respectively.
doi:10.1371/journal.pone.0083685.g006
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with VD, provides further evidence of a direct role of VD on
adiponectin production. This is also supported by the demonstra-
tion of stable ghrelin levels, which are a precocious index of the
recovery of an ideal body weight when they increase. The second
limitation is we performed just two adiponectin evaluations after
VD treatment, with more prolonged studies and more frequent
time points needed to surely prove a connection. Despite this,
when we weighted adiponectin for cofounders, which may
influence its secretion, the significance was maintained suggesting
an influence of the VD treatment. Thirdly, this is a pilot study to
investigate whether proteins identified via a proteomic approach
are directly modulated by VD, in the case of adiponectin, an in
vitro adipose tissue model. Notably, more studies are needed in the
future to understand the biological mechanisms and whether other
proteins are implicated. In support of the findings however, a diet
rich in VD has been shown to increase adiponectin synthesis in
swine epicardial adipose tissue [58].
VD has been proposed as a promising strategy for the
prevention of obesity and the development of its associated
complications. While VD has a long history, the ‘‘concert’’ of
metabolic signaling pathways that link obesity with VD status
remain undefined. In the present study, we used a proteomic
approach to study the global plasmatic changes between VD
deficient and normal obese pediatric subjects identifying that the
multimeric forms of adiponectin, in particular the HMW form are
plasmatic biomarkers that could provide a mechanistic link
between VD deficiency and pediatric obesity, with total plasma
levels increasing with cholecalciferol supplementation. By using
the in vitro 3T3-L1 adipocyte cell model system, a direct effect of
1a,25-(OH)2D3 at low pharmacological concentrations was
demonstrated. While the mechanism of VD control over
adiponectin remains to be clearly defined, the upregulation of
the ER-chaperon DsbA-L, suggests that this may be a post-
transcriptional dependent event.
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